← Back to guidelines
Cardiology107 papers

Endocardial fibroelastosis

Last edited: 28 days ago

Overview

Endocardial fibroelastosis (EFE) is a condition characterized by excessive fibrosis of the endocardium, leading to impaired ventricular function and often associated with congenital heart disease, particularly in infants and young children 15.

Diagnosis

  • Clinical Presentation: Symptoms may include dyspnea, tachycardia, and signs of heart failure 13.
  • Electrocardiography (ECG): Abnormal ECG findings indicative of left ventricular overload 3.
  • Echocardiography: Essential for visualizing left ventricular hypertrophy and function 3.
  • Cardiac Catheterization: Useful for measuring left ventricular end-diastolic pressure and ejection fraction 3.
  • Histopathology: Confirms diagnosis through characteristic fibrotic changes in endocardial tissue 5.
  • Genetic Testing: Considered in familial cases to assess inheritance patterns 16.
  • Management

  • Medical Management: Diuretics, ACE inhibitors, and beta-blockers to manage heart failure symptoms 3.
  • Symptom Relief: Focus on alleviating symptoms and monitoring progression 3.
  • Surgical Interventions: Considered in severe cases with refractory heart failure 3.
  • Supportive Care: Includes nutritional support and management of complications 3.
  • Special Populations

  • Pediatrics: EFE predominantly affects infants and young children, with variable outcomes based on severity and treatment 135.
  • Genetic Considerations: Familial cases suggest potential autosomal or X-linked dominant inheritance with reduced penetrance 16.
  • Key Recommendations

  • Conduct thorough family history assessment to identify potential hereditary patterns in EFE management (Evidence: Moderate 16).
  • Utilize echocardiography and cardiac catheterization for monitoring disease progression and response to therapy (Evidence: Moderate 3).
  • Implement medical management strategies including diuretics and ACE inhibitors for symptom control in symptomatic patients (Evidence: Weak 3).
  • References

    1 Hanukoglu A, Fried D, Somekh E. Inheritance of familial primary endocardial fibroelastosis. Clinical pediatrics 1986. link 2 Hoch-Ligeti C, Harris PN, Stewart HL. Endocardial tumors induced by carbamate or fluorenylacetamide derivatives in rats. Journal of the National Cancer Institute 1983. link 3 Schneeweiss A, Shem-Tov A, Neufeld HN. Persistent left ventricular disease in clinically "cured" primary endocardial fibroelastosis. British heart journal 1983. link 4 Berman JJ, Rice JM, Reddick R. Endocardial schwannomas in rats. Their characterization by light and electron microscopy. Archives of pathology & laboratory medicine 1980. link 5 Factor SM. Endocardial fibroelastosis: myocardial and vascular alterations associated with viral-like nuclear particles. American heart journal 1978. link90012-1) 6 Westwood M, Harris R, Burn JL, Barson AJ. Heredity in primary endocardial fibroelastosis. British heart journal 1975. link

    Original source

    1. [1]
      Inheritance of familial primary endocardial fibroelastosis.Hanukoglu A, Fried D, Somekh E Clinical pediatrics (1986)
    2. [2]
      Endocardial tumors induced by carbamate or fluorenylacetamide derivatives in rats.Hoch-Ligeti C, Harris PN, Stewart HL Journal of the National Cancer Institute (1983)
    3. [3]
      Persistent left ventricular disease in clinically "cured" primary endocardial fibroelastosis.Schneeweiss A, Shem-Tov A, Neufeld HN British heart journal (1983)
    4. [4]
      Endocardial schwannomas in rats. Their characterization by light and electron microscopy.Berman JJ, Rice JM, Reddick R Archives of pathology & laboratory medicine (1980)
    5. [5]
    6. [6]
      Heredity in primary endocardial fibroelastosis.Westwood M, Harris R, Burn JL, Barson AJ British heart journal (1975)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG